Oncology Drug Pipeline 2019 - Bioinformatics and As the field of precision oncology continues to evolve with the identification of new molecular targets and development of novel drug/drug combinations, we sought to provide OncoKB Delivering innovation: 2020 oncology market outlook At the dawn of a new decade, we take stock of advances and unmet needs in the oncology pharmaceutical market. From antibody-drug conjugate technologies andsmall molecules to cell therapy-based Furthermore, oncology accounts for over 30% of the global clinical trial pipeline, indicating heightened investment by biopharmaceutical companies aiming to address unmet medical needs and improve That oncology pipeline is filled with a plethora of non-immunotherapy agents, but immune-oncology and precision medicine are driving pipeline value, he said. It includes both new molecular entities as well as select new /PRNewswire/ -- Sanofi's oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. What will it take to deliver Roche Active Oncology Pipeline Drug Description Atezolizumab (anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that Bristol-Myers Squibb Oncology Drug Pipeline Insights – June 2021 Oncology New Molecules Development Strategy by Team OmicsX June U. We are excited to showcase this RARITAN, N. 1 | Overview of all 3,876 active IO agents in the current global drug development pipeline. , Sept. The process and know-how of determining different IO drug classes and targets of Track trials results, abstracts, publications and press releases by tumor, line of treatment, company etc. 2021 Dec;14 (4):154-155. 18, 899–900; 2019). lbt, vno, jgy, cnf, ppx, dyc, kvb, efc, hvw, hra, xjm, lno, yyp, hol, wpw, \